Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat

Neuropeptides

Volumn 44, Issue 4, 2010, Pages 285-291

  Gulec, Guldal ^a   Isbil Buyukcoskun, Naciye ^a   Kahveci, Nevzat ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Arginine vasopressin; Elevated plus maze; GLP 1; Nitric oxide; Open field; Rat; Seizure

Indexed keywords

ARGIPRESSIN; GLUCAGON LIKE PEPTIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PILOCARPINE; SODIUM CHLORIDE; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MAZE TEST; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RESPONSE TIME; SEIZURE; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY; EXPLORATORY BEHAVIOR; GLUCAGON-LIKE PEPTIDE 1; INJECTIONS, INTRAVENTRICULAR; MALE; MOTOR ACTIVITY; MUSCARINIC AGONISTS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; SEIZURES; VASOPRESSINS;

EID: 77953536456     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.02.002     Document Type: Article

References (37)

1. Abbas T., Faivre E., Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice. Interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 2009, 205:265-271.
2. Bojanowska E., Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul. Pept. 2000, 91:75-81.
3. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
4. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002, 122:531-544.
5. Drucker D.J., Asa S. Glucagon gene expression in vertebrate brain. J. Biol. Chem. 1988, 263:13475-13478.
6. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature 2003, 9(9):1173-1179.
7. Elliot R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h patterns. J. Endocrinol. 1993, 138:159-166.
8. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 1995, 7:2294-2300.
9. Habib K.E., Gold P.W., Chrousos G.P. Neuroendocrinology of stress. Endocrinol. Metab. Clin. North Am. 2001, 30:695-728.
10. Isbil-Buyukcoskun N., Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul. Pept. 2004, 118:33-38.
11. Isbil-Buyukcoskun N., Gulec G. Effects of centrally injected GLP-1 in various experimental models of gastric mucosal damage. Peptides 2004, 25:1179-1183.
12. Isbil-Buyukcoskun N., Gulec G. Investigation of the mechanisms involved in the central effects of glucagon-like peptide-1 on ethanol-induced gastric mucosal lesions. Regul. Pept. 2005, 128:57-62.
13. Isbil-Buyukcoskun N., Gulec G., Ozluk K. Protective effect of centrally-injected glucagon-like peptide-1 on reserpine-induced gastric mucosal lesions in rat: possible mechanisms. Turk. J. Gastroenterol. 2006, 17(1):1-6.
14. Iwai T., Suzuki M., Kobayashi K., Mori K., Mogi Y., Oka J. The influences of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. Neurosci. Res. 2009, 64(1):67-74.
15. Jin S.L., Han V.K., Simmons J.G., Towle A.C., Lauder J.M., Lund P.K. Distribution of glucagon-like peptide-1 (GLP-1), glucagon, and glisentin in the rat brain: an immunocytochemical study. J. Comp. Neurol. 1988, 271:519-532.
16. Jun-Ichiro O., Suzuki E., Kondo Y. Endogenous GLP-1 is involved in β-amyloid protein-induced memory impairment and hippocampal neuronal death in rats. Brain Res. 2000, 878:194-198.
17. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr. Rev. 1999, 20(6):876-913.
18. Kinzig K.P., D'Alessio D.A., Herman J.P., Sakai R.R., Vahl T.P., Figueiredo H.F., Murphy E.K., Seeley R.J. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J. Neurosci. 2003, 23(15):6163-6170.
19. Klugmann M., Leichtlein C.B., Symes C.W., Klaussner B.C., Brooks A.I., Young D., During J. A novel role of circadian transcription factor DBP in hippocampal plasticity. Mol. Cell. Neurosci. 2006, 31:303-314.
20. Larsen P.J., Tang-Christensen M., Holst J.J., Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77:257-270.
21. Larsen P.J., Tang-Christensen M., Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997, 138:4445-4455.
22. List J.F., He H., Habener J.F. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul. Pept. 2006, 134:149-157.
23. MacLusky N.J., Cook S., Scrocchi L., Shin J., Kim J., Vaccarino F., Asa S.L., Drucker D.J. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 signaling. Endocrinology 2000, 141(2):752-762.
24. McMahon L.R., Wellman P.J. PVN infusion of GLP-1-(7-39) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am. J. Physiol. 1998, 274:R23-R29.
25. Möller C., Sommer W., Thorsell A., Rimondini R., Heilig M. Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:119-122.
26. Nystrom T., Gonon A.T., Sjoholm A., Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 2005, 125:173-177.
27. Perry T., Greig N.H. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimers Dis. 2002, 4(6):487-496.
28. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302(3):881-888.
29. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72(5):603-612.
30. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32(3):281-294.
31. Shimizu I., Hirota M., Obhoshi C., Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987, 121(3):1076-1082.
32. Tang-Christensen M., Göke R., Moller M., Sheikh S.P. GLP-1 and its receptors in the central nervous system are powerful regulators of autonomic functions in the brain. Soc. Neurosci. Abstr. 1994, 24:561-565.
33. Tauchi M., Zhang R., D'Alessio D.A., Stern J.E., Herman J.P. Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei. J. Chem. Neuroanat. 2008, 36:144-149.
34. Tolessa T., Gutniak M., Holst J.J., Efendic S., Hellstrom P.M. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J. Clin. Invest. 1998, 102:764-774.
35. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379(6560):69-72.
36. Wamil A., Croiset G., Kleinrok Z., De Wied D. Beneficial effects of ACTH 4-10 on pilocarpine induced seizures. Neurosci. Res. Commun. 1989, 4(2):109-116.
37. Zueco J.A., Esquifino A.I., Chowen J.A., Alvarez E., Castrillon P.O., Blazquez E. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36) amide on vasopressin and oxytocin release. J. Neurochem. 1999, 72(1):10-16.